Form 8-K - Current report:
SEC Accession No. 0001193125-26-159189
Filing Date
2026-04-16
Accepted
2026-04-16 16:47:39
Documents
16
Period of Report
2026-04-15
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K achv-20260415.htm   iXBRL 8-K 105371
2 EX-4.1 achv-ex4_1.htm EX-4.1 206203
3 EX-4.2 achv-ex4_2.htm EX-4.2 165575
4 EX-10.1 achv-ex10_1.htm EX-10.1 420270
5 EX-10.2 achv-ex10_2.htm EX-10.2 203519
6 EX-99.1 achv-ex99_1.htm EX-99.1 31958
7 GRAPHIC img9551541_0.jpg GRAPHIC 21022
8 GRAPHIC img9551541_1.gif GRAPHIC 13849
  Complete submission text file 0001193125-26-159189.txt   1509539

Data Files

Seq Description Document Type Size
9 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT achv-20260415.xsd EX-101.SCH 51387
19 EXTRACTED XBRL INSTANCE DOCUMENT achv-20260415_htm.xml XML 6342
Mailing Address 22722 29TH DR. SE SUITE 100 SEATTLE WA 98021
Business Address 22722 29TH DR. SE SUITE 100 SEATTLE WA 98021 425-686-1500
ACHIEVE LIFE SCIENCES, INC. (Filer) CIK: 0000949858 (see all company filings)

EIN.: 954343413 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 033-80623 | Film No.: 26868218
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)